Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. director Joshua Lehrer-Graiwer received a grant of stock options covering 64,000 shares of common stock. The options have an exercise price of $8.08 per share and are scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lehrer-Graiwer Joshua

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	64,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 64,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options Granted: 64,000 options Exercise Price: $8.08 per share Underlying Shares: 64,000 shares +4 more

7 metrics

Options Granted 64,000 options Stock Option (right to buy) granted to director

Exercise Price $8.08 per share Conversion or exercise price for granted options

Underlying Shares 64,000 shares Common Stock underlying the options

Grant Date April 23, 2026 Option grant date per footnote

Vesting End Date April 23, 2029 Monthly vesting schedule end, subject to continued service

Expiration Date April 22, 2036 Option expiration date

Post-transaction Options 64,000 derivative securities Total options held from this grant after transaction

Key Terms

Stock Option (right to buy), exercise price, vest in equal monthly installments, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 8.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"is scheduled to vest in equal monthly installments until April 23, 2029"

expiration date financial

"expiration_date: 2036-04-22T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lehrer-Graiwer Joshua

(Last)

(First)

(Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.08	04/23/2026		A		64,000		⁽¹⁾	04/22/2036	Common Stock	64,000	$0.00	64,000	D

Explanation of Responses:

1. This option was granted on April 23, 2026 and is scheduled to vest in equal monthly installments until April 23, 2029, subject to continued service.

	/s/ Alan Musso as attorney-in-fact for Joshua Lehrer-Graiwer	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report for Joshua Lehrer-Graiwer?

Fulcrum Therapeutics reported that director Joshua Lehrer-Graiwer received a grant of stock options for 64,000 shares of common stock. These options were awarded on April 23, 2026 as compensation, rather than as an open-market purchase or sale of existing shares.

What is the exercise price of the new Fulcrum Therapeutics (FULC) stock options?

The granted stock options have an exercise price of $8.08 per share. This means Lehrer-Graiwer can buy Fulcrum Therapeutics common stock at $8.08 for each of the 64,000 option shares if and when the options vest and are exercised.

How many Fulcrum Therapeutics (FULC) option shares were granted in this Form 4 filing?

The filing shows a grant of stock options covering 64,000 shares of Fulcrum Therapeutics common stock. Following this transaction, the total option position reported for this grant is 64,000 derivative securities, reflecting a single compensation award rather than multiple separate transactions.

When do Joshua Lehrer-Graiwer’s Fulcrum Therapeutics (FULC) options vest?

The options granted on April 23, 2026 are scheduled to vest in equal monthly installments until April 23, 2029. Vesting is conditioned on continued service, meaning the director must remain in service to receive each monthly vested portion of the award.

When do the reported Fulcrum Therapeutics (FULC) stock options expire?

The stock options reported in the Form 4 are scheduled to expire on April 22, 2036. After this expiration date, any unexercised options from the 64,000-share grant will no longer be exercisable, even if they had previously vested during the vesting schedule.